Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

<p>Personalis offers genomic sequencing to bio-pharmaceutical companies by fully analyzing sample tissue data of cancer patients. It provides its bio-pharmaceutical customers with information on all of the approximately 20,000 human genes alongside immune system information, as opposed to many cancer panels that cover roughly 50 to 500 genes which puts the company with a distinct competitive advantage over its competition.</p>
<p>The company has filed for an IPO to raise funds of approximately US$100m and has set its IPO price at US$15 per share, which implies a valuation of US$323m. We see good potential for the company where clinical trials and drug development requires significant cancer genetic information of patients where Personalis could play a significant role and make use of the market opportunity presented. Due to a strong industry coupled with strong growth in revenues and a solid balance sheet with positive operating cash flows, we believe the stock is attractive. That being said, the investors should be vary of Personalis’ revenues being highly concentrated into a few customers which exposes the company to substantial risk of losing revenues due to cancellation of contracts.</p>

Personalis offers genomic sequencing to bio-pharmaceutical companies by fully analyzing sample tissue data of cancer patients. It provides its bio-pharmaceutical customers with information on all of the approximately 20,000 human genes alongside immune system information, as opposed to many cancer panels that cover roughly 50 to 500 genes which puts the company with a distinct competitive advantage over its competition.
The company has filed for an IPO to raise funds of approximately US$100m and has set its IPO price at US$15 per share, which implies a valuation of US$323m. We see good potential for the company where clinical trials and drug development requires significant cancer genetic information of patients where Personalis could play a significant role and make use of the market opportunity presented. Due to a strong industry coupled with strong growth in revenues and a solid balance sheet with positive operating cash flows, we believe the stock is attractive. That being said, the investors should be vary of Personalis’ revenues being highly concentrated into a few customers which exposes the company to substantial risk of losing revenues due to cancellation of contracts.

Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market

Personalis Inc

Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market